Objective: To identify baseline factors associated with disease activity in patients with relapsing–remitting multiple sclerosis (RRMS) under teriflunomide treatment. Methods: This was an independent, multi-centre, retrospective post-marketing study. We analysed data of 1,507 patients who started teriflunomide since October 2014 and were regularly followed in 28 Centres in Italy. We reported the proportions of patients who discontinued treatment (after excluding 32 lost to follow-up) and who experienced clinical disease activity, i.e., relapse(s) and/or confirmed disability worsening, as assessed by the Expanded Disability Status Scale (EDSS). Decision tree-based analysis was performed to identify baseline factors associated with clinical disease activity during teriflunomide treatment. Results: At database lock (September 2020), approximately 29% of patients (430 out of 1,475) discontinued teriflunomide because of disease activity (~ 46%), adverse events (~ 37%), poor tolerability (~ 15%), pregnancy planning (~ 2%). Approximately 28% of patients experienced disease activity over a median follow-up of 2.75 years: ~ 9% had relapses but not disability worsening; ~ 13% had isolated disability worsening; ~ 6% had both relapses and disability worsening. The most important baseline factor associated with disease activity (especially disability worsening) was an EDSS > 4.0 (p < 0.001). In patients with moderate disability level (EDSS 2.0–4.0), disease activity occurred more frequently in case of ≥ 1 pre-treatment relapses (p = 0.025). In patients with milder disability level (EDSS < 2.0), disease activity occurred more frequently after previous exposure to ≥ 2 disease-modifying treatments (p = 0.007). Conclusions: Our study suggests a place-in-therapy for teriflunomide in naïve patients with mild disability level or in those who switched their initial treatment for poor tolerability. Adverse events related with teriflunomide were consistent with literature data, without any new safety concern.

Real world experience with teriflunomide in multiple sclerosis: the TER-Italy study / Bucello, S.; Annovazzi, P.; Ragonese, P.; Altieri, M.; Barcella, V.; Bergamaschi, R.; Bianchi, A.; Borriello, G.; Buscarinu, M. C.; Callari, G.; Capobianco, M.; Capone, F.; Cavalla, P.; Cavarretta, R.; Cortese, A.; De Luca, G.; Di Filippo, M.; Dattola, V.; Fantozzi, R.; Ferraro, E.; Filippi, M. M.; Gasperini, C.; Grimaldi, L. M. E.; Landi, D.; Re, M. L.; Mallucci, G.; Manganotti, P.; Marfia, G. A.; Mirabella, M.; Perini, P.; Pisa, M.; Realmuto, S.; Russo, M.; Tomassini, V.; Torri-Clerici, V. L. A.; Zaffaroni, M.; Zuliani, C.; Zywicki, S.; Filippi, M.; Prosperini, L.. - In: JOURNAL OF NEUROLOGY. - ISSN 0340-5354. - 268:8(2021), pp. 2922-2932. [10.1007/s00415-021-10455-3]

Real world experience with teriflunomide in multiple sclerosis: the TER-Italy study

Altieri M.;Buscarinu M. C.;Gasperini C.;Prosperini L.
2021

Abstract

Objective: To identify baseline factors associated with disease activity in patients with relapsing–remitting multiple sclerosis (RRMS) under teriflunomide treatment. Methods: This was an independent, multi-centre, retrospective post-marketing study. We analysed data of 1,507 patients who started teriflunomide since October 2014 and were regularly followed in 28 Centres in Italy. We reported the proportions of patients who discontinued treatment (after excluding 32 lost to follow-up) and who experienced clinical disease activity, i.e., relapse(s) and/or confirmed disability worsening, as assessed by the Expanded Disability Status Scale (EDSS). Decision tree-based analysis was performed to identify baseline factors associated with clinical disease activity during teriflunomide treatment. Results: At database lock (September 2020), approximately 29% of patients (430 out of 1,475) discontinued teriflunomide because of disease activity (~ 46%), adverse events (~ 37%), poor tolerability (~ 15%), pregnancy planning (~ 2%). Approximately 28% of patients experienced disease activity over a median follow-up of 2.75 years: ~ 9% had relapses but not disability worsening; ~ 13% had isolated disability worsening; ~ 6% had both relapses and disability worsening. The most important baseline factor associated with disease activity (especially disability worsening) was an EDSS > 4.0 (p < 0.001). In patients with moderate disability level (EDSS 2.0–4.0), disease activity occurred more frequently in case of ≥ 1 pre-treatment relapses (p = 0.025). In patients with milder disability level (EDSS < 2.0), disease activity occurred more frequently after previous exposure to ≥ 2 disease-modifying treatments (p = 0.007). Conclusions: Our study suggests a place-in-therapy for teriflunomide in naïve patients with mild disability level or in those who switched their initial treatment for poor tolerability. Adverse events related with teriflunomide were consistent with literature data, without any new safety concern.
2021
Multiple sclerosis; Oral drugs; Teriflunomide; Crotonates; Humans; Hydroxybutyrates; Italy; Nitriles; Retrospective Studies; Toluidines; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting
01 Pubblicazione su rivista::01a Articolo in rivista
Real world experience with teriflunomide in multiple sclerosis: the TER-Italy study / Bucello, S.; Annovazzi, P.; Ragonese, P.; Altieri, M.; Barcella, V.; Bergamaschi, R.; Bianchi, A.; Borriello, G.; Buscarinu, M. C.; Callari, G.; Capobianco, M.; Capone, F.; Cavalla, P.; Cavarretta, R.; Cortese, A.; De Luca, G.; Di Filippo, M.; Dattola, V.; Fantozzi, R.; Ferraro, E.; Filippi, M. M.; Gasperini, C.; Grimaldi, L. M. E.; Landi, D.; Re, M. L.; Mallucci, G.; Manganotti, P.; Marfia, G. A.; Mirabella, M.; Perini, P.; Pisa, M.; Realmuto, S.; Russo, M.; Tomassini, V.; Torri-Clerici, V. L. A.; Zaffaroni, M.; Zuliani, C.; Zywicki, S.; Filippi, M.; Prosperini, L.. - In: JOURNAL OF NEUROLOGY. - ISSN 0340-5354. - 268:8(2021), pp. 2922-2932. [10.1007/s00415-021-10455-3]
File allegati a questo prodotto
File Dimensione Formato  
Bucello_Real world experience_2021.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 2.08 MB
Formato Adobe PDF
2.08 MB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1565367
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 16
  • ???jsp.display-item.citation.isi??? 13
social impact